Stryker Co. (NYSE:SYK) is LGT Capital Partners LTD.'s 10th Largest Position

LGT Capital Partners LTD. lessened its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 7.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 281,690 shares of the medical technology company's stock after selling 22,082 shares during the period. Stryker accounts for 3.5% of LGT Capital Partners LTD.'s portfolio, making the stock its 10th largest holding. LGT Capital Partners LTD. owned 0.07% of Stryker worth $101,763,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of SYK. Wealth Enhancement Advisory Services LLC raised its stake in Stryker by 78.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company's stock valued at $45,260,000 after purchasing an additional 58,673 shares during the last quarter. OFI Invest Asset Management grew its holdings in shares of Stryker by 3,210.9% during the second quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company's stock worth $1,062,000 after purchasing an additional 3,243 shares during the last quarter. Tidal Investments LLC raised its position in shares of Stryker by 14.2% during the first quarter. Tidal Investments LLC now owns 13,558 shares of the medical technology company's stock worth $4,853,000 after acquiring an additional 1,681 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Stryker by 2.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company's stock worth $210,289,000 after purchasing an additional 16,504 shares during the last quarter. Finally, Fiera Capital Corp lifted its stake in Stryker by 42.1% in the second quarter. Fiera Capital Corp now owns 16,713 shares of the medical technology company's stock valued at $5,687,000 after buying an additional 4,948 shares during the period. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

SYK stock traded down $0.96 during mid-day trading on Tuesday, reaching $388.44. The company's stock had a trading volume of 781,424 shares, compared to its average volume of 1,268,036. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The company's 50 day moving average is $364.61 and its two-hundred day moving average is $347.98. The stock has a market cap of $148.08 billion, a PE ratio of 41.74, a P/E/G ratio of 2.94 and a beta of 0.91. Stryker Co. has a fifty-two week low of $285.79 and a fifty-two week high of $398.20.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to analysts' expectations of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company's revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.46 EPS. Equities research analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Wall Street Analyst Weigh In

SYK has been the subject of several research analyst reports. Wells Fargo & Company boosted their price objective on Stryker from $381.00 to $405.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. StockNews.com raised shares of Stryker from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. Wolfe Research began coverage on shares of Stryker in a report on Tuesday, September 10th. They set an "outperform" rating and a $405.00 price target for the company. Robert W. Baird boosted their target price on Stryker from $378.00 to $405.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $420.00 target price (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $393.65.

Insider Buying and Selling

In other news, insider Viju Menon sold 600 shares of the business's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares of the company's stock, valued at approximately $3,219,495. The trade was a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin Lobo sold 57,313 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 67,381 shares of company stock valued at $24,825,275 in the last ninety days. Company insiders own 5.50% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.